Interatrial Shunt Devices Market Report 2025

The interatrial shunt devices market size has grown rapidly in recent years. It will grow from $2.63 billion in 2024 to $2.9 billion in 2025 at a compound annual growth rate (CAGR) of 10.5%. The growth during the historic period can be attributed to increasing clinical evidence validating efficacy and safety, heightened demand for effective pulmonary hypertension management, a rising incidence of related comorbidities, more regulatory approvals for investigational shunt systems, and a growing preference for outpatient and ambulatory cardiac care.

The interatrial shunt devices market size is expected to see rapid growth in the next few years. It will grow to $4.28 billion in 2029 at a compound annual growth rate (CAGR) of 10.2%. The expected growth in the forecast period can be linked to the increasing prevalence of heart failure, an expanding elderly population, heightened awareness of minimally invasive cardiac procedures, rising healthcare spending, and greater adoption of catheter-based treatments. Key trends during this period include innovations in shunt device materials, technology-driven miniaturization of interventional devices, integration of real-time imaging and navigation technologies, advancements in catheter-based delivery methods, and improvements in hemodynamic monitoring systems.

The increasing prevalence of heart failure is expected to drive the growth of the interatrial shunt devices market in the coming years. Heart failure is a condition where the heart cannot pump blood effectively, leading to insufficient delivery of oxygen and nutrients to the body’s tissues. The rise in heart failure cases is largely due to the growing incidence of hypertension, which gradually weakens the heart’s pumping ability. Interatrial shunt devices assist in managing heart failure by creating a small opening between the left and right atria, allowing excess pressure from the overloaded left atrium to be relieved by transferring it to the right atrium. This helps reduce pulmonary congestion and alleviates symptoms. For example, in September 2024, the Heart Failure Society of America, a US-based professional organization, reported that approximately 6.7 million Americans aged 20 and older were living with heart failure in 2024. This figure is expected to rise to 11.4 million by 2050. Consequently, the growing prevalence of heart failure is propelling the expansion of the interatrial shunt devices market.

Key players in the interatrial shunt devices market are concentrating on innovative developments, such as first-in-human (FIH) clinical trials to assess the safety and effectiveness of new shunt technologies aimed at lowering left atrial pressure in heart failure patients. A first-in-human clinical trial is the initial phase of testing a new medical device or drug in humans to evaluate safety, tolerability, and early efficacy following successful preclinical research. For instance, in January 2025, Adona Medical Inc., a US-based medical technology company, completed enrollment for its first-in-human (FIH) clinical trial, ATHENS-HF, involving a novel interatrial shunt designed for heart failure treatment. This device is among the first to combine therapeutic shunting with integrated bi-atrial pressure monitoring, offering a more adaptive and personalized method of managing heart failure.

In October 2024, Johnson & Johnson, a US-based pharmaceutical company, acquired V-Wave Ltd. for an undisclosed sum. This acquisition aims to strengthen Johnson & Johnson’s cardiovascular portfolio by adding advanced heart failure therapies and addressing critical unmet needs in the sector. V-Wave Ltd. is an Israel-based medical device firm specializing in innovative interatrial shunt devices.

Major players in the interatrial shunt devices market are Johnson & Johnson, Abbott Laboratories, Medtronic plc., Terumo Corporation, Edwards Lifesciences Corporation, Cook Medical, Integra LifeSciences Holdings Corporation, Lepu Medical Technology (Beijing) Co. Ltd., B. Braun Melsungen AG., W. L. Gore & Associates Inc., Venus Medtech Inc., Occlutech Holding AG., Wuhan Vickor Medical Technology Co. Ltd., Corvia Medical Inc., Xeltis BV, Alleviant Medical Inc., Cerevasc Inc., Adona Medical Inc., Carag AG., InterShunt Technologies Inc.

North America was the largest region in the interatrial shunt devices market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in interatrial shunt devices report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the interatrial shunt devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The interatrial shunt devices market consists of sales of catheter-based delivery tools, transseptal access kits, monitoring accessories, and procedure-specific consumables. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

The interatrial shunt devices market research report is one of a series of new reports that provides interatrial shunt devices market statistics, including the interatrial shunt devices industry's global market size, regional shares, competitors with the interatrial shunt devices market share, detailed interatrial shunt devices market segments, market trends and opportunities, and any further data you may need to thrive in the interatrial shunt devices market. This interatrial shunt devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Interatrial shunt devices are implantable medical tools developed to create a controlled passage between the left and right atria of the heart, aiming to lower pressure and alleviate symptoms in heart failure patients. These devices help redirect blood flow from the left atrium to the right atrium, effectively reducing elevated left atrial pressure associated with heart failure.

The primary types of interatrial shunt devices include implantable shunt devices and temporary shunt devices. Implantable shunt devices are designed to create a regulated connection between different body compartments and are typically used to redirect fluid or pressure for therapeutic purposes. These devices can be placed via surgical procedures or transcatheter methods. Common construction materials include nitinol, polyester, and polypropylene. They are primarily used in the treatment of congenital heart defects, heart failure, and stroke prevention, and are employed across various healthcare settings such as hospitals, ambulatory surgical centers, cardiac catheterization labs, and others.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.